CPHI North America is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Exhibitor Spotlight

Don’t forget to bring your headphones!

This year, our theaters on the show floor will be ‘silent theaters’, bring your own headphones to listen to speaker audio through your mobile device.

Bobby Sciscento
Senior Formulations Scientist
Mitchell Slade
PL Developments/Avéma Pharma Solutions
COO, PL Developments and President, Avéma Gummy Solutions


Location: Conference Theater 2 | Date: May 7th 2024

11:00-11:25 (EST)
Using Better Data Management For Predictive Scale-Up Parameter Estimation And Supply Chain Planning

In the rapidly evolving digital ecosystem of pharmaceutical development, there is a growing importance for the integration and management of diverse data to help drive affordable success. This presentation will delve into the realm of big data and how comprehensive data management impacts parameter prediction and refinement for scale-up models and provides valuable forecast insight to support a more cost-effective manufacturing campaign. How can we harness technological solutions to optimize data utilization across the process development data space and create transformative impact within the pharmaceutical industry, to drive efficiency and foster innovation? Join us as we explore the transformative potential of data-driven strategies in shaping the future of biopharmaceutical manufacturing.

Location: Conference Theater 2 | Date: May 8th 2024

11:00-11:25 (EST)
The Promise of Gummies as a Drug Delivery System

The global gummy vitamin market is expected to reach 10.6 billion by 2025 and gummies are gaining traction as a drug delivery system -- especially for children and seniors who resist taking pills, capsules and liquids. Mitchell Slade, who brings more than 20 years of gummy manufacturing experience at Nature’s Bounty to the table, will address the challenges of developing gummies beyond supplements, such ensuring consistent dosage, production and taste. Avéma/PLD has a world-class GDUFA facility that is CFR 211 and CFR 111 certified, uses a starchless gummy manufacturing process and brings 40+ years of formulating experience to the development of innovative drug delivery systems.

14:30-14:55 (EST)
Expanding the OSD toolbox with an industry-based approach to lipid and surfactant adsorption onto dry powder excipients to increase the dissolution rate of BCS Class II and Class IV active pharmaceutical ingredients (API’s)

Common high-performance lipids and surfactants were used to improve the dissolution rate of furosemide as a model compound for BCS Class II and Class IV active pharmaceutical ingredients. Furosemide equilibrium solubility was measured throughout an HLB range (1-16) of liquid lipids and surfactants. Furosemide tablets were then manufactured using high shear granulation to absorb the solubilized and suspended furosemide onto microcrystalline cellulose (Avicel PH101).

The granulations were then compressed using a rotary tablet press and standard tablet tooling. Finished tablets were analyzed to compare dissolution rates using 0.1 N HCl media and USP Apparatus II. Higher equilibrium solubility yielded increased dissolution rates for furosemide tablets compared to directly compressed furosemide tablets.

Full agenda
Full conference agendas
Our community
Moments from last year
img missing
img missing
Pharma professional showing individual work on a laptop at CPHI North America
Join us at CPHI North America